No cancer can be guaranteed cured in the way a broken bone heals, but some types have such low survival rates that doctors rarely use the word “cure” at all. Pancreatic cancer, glioblastoma, advanced lung cancer, anaplastic thyroid cancer, and certain childhood brain tumors are among the hardest to treat successfully. What “not curable” actually means, though, is more nuanced than it sounds.
Why Doctors Rarely Say “Cured”
In oncology, a cure means no traces of cancer remain after treatment and the cancer will never return. That’s a high bar, and most oncologists avoid the word entirely. What they can say is that there’s “no evidence of disease” at a given point in time. If someone stays in complete remission for five years or more, some doctors consider that a practical cure, but cancer cells can linger in the body for years and potentially reactivate. Most recurrences happen within the first five years, but late relapses do occur.
This is why the phrase “not curable” exists on a spectrum. At one end are cancers where long-term remission is common and recurrence is rare. At the other end are cancers where even short-term remission is difficult to achieve. The cancers below fall toward that harder end.
Pancreatic Cancer
Pancreatic cancer is often cited as the least curable common cancer, and the numbers bear that out. When it has already spread to distant organs, which is the case for about half of patients at diagnosis, the five-year survival rate is just 3.4%. Even when caught early and still confined to the pancreas, the five-year survival rate is only about 44%, far lower than the localized survival rate for most other cancers.
The pancreas sits deep in the abdomen, surrounded by major blood vessels, making surgery difficult. Pancreatic tumors also tend to resist chemotherapy effectively and often produce few noticeable symptoms until the disease is advanced. By the time most people experience jaundice, unexplained weight loss, or persistent back pain, the cancer has typically spread beyond what surgery can remove.
Glioblastoma
Glioblastoma is the most aggressive primary brain tumor in adults. Even with standard treatment (surgery, radiation, and chemotherapy), the median life expectancy is about 12 to 18 months after diagnosis. The overall five-year survival rate for brain cancer is 36% when localized, but glioblastoma specifically performs far worse than that average suggests.
What makes glioblastoma so difficult is how it grows. Rather than forming a neat, removable mass, it sends thread-like extensions into surrounding healthy brain tissue, making complete surgical removal essentially impossible. The cells left behind regrow quickly, and the blood-brain barrier limits which drugs can reach the tumor effectively.
Advanced Lung Cancer
Lung cancer is the leading cause of cancer death worldwide, largely because it’s frequently diagnosed after it has spread. For non-small cell lung cancer that has reached distant organs (bones, brain, liver, or the opposite lung), the five-year survival rate is 12%. Small cell lung cancer, a faster-growing subtype, has even grimmer numbers at the distant stage.
Immunotherapy and targeted therapies have improved outcomes meaningfully in recent years, and people diagnosed today may fare better than these statistics reflect, since survival data is based on patients diagnosed between 2015 and 2021. Some patients with specific genetic mutations in their tumors respond dramatically to targeted drugs, living years longer than previously expected. But for the majority of people with stage IV lung cancer, the goal of treatment shifts from cure to extending life and managing symptoms.
Anaplastic Thyroid Cancer
Most thyroid cancers are highly treatable. Anaplastic thyroid cancer is the exception. It accounts for only about 1 to 2% of all thyroid cancers but is one of the most lethal cancers of any type. The five-year survival rate across all stages is just 10%. When it has spread to distant sites, that drops to 5%. Even when still localized, the five-year survival is only 45%, which is unusually poor for a cancer caught before it spreads.
Anaplastic thyroid cancer grows and spreads extremely fast. It often invades nearby structures in the neck (the windpipe, esophagus, and major blood vessels) within weeks, and it responds poorly to the radioactive iodine treatment that works well against other thyroid cancers.
DIPG in Children
Diffuse intrinsic pontine glioma, or DIPG, is a childhood brain tumor that grows in the pons, a part of the brainstem controlling essential functions like breathing, heart rate, and swallowing. Most children with DIPG do not survive longer than two years after diagnosis. It is among the most devastating diagnoses in pediatric oncology.
Surgery isn’t an option because the tumor is woven into brain tissue that controls vital functions. Radiation can temporarily slow growth and relieve symptoms, but the tumor almost always progresses. Decades of clinical trials have failed to find a chemotherapy regimen that significantly extends survival, though research continues.
Why Some Cancers Resist Treatment
The cancers listed above share a common biological challenge: tumor heterogeneity. The cells within a single tumor are not identical. Different cells carry different genetic mutations and rely on different survival mechanisms. When a drug kills the cells that are sensitive to it, resistant cells survive and multiply to fill the gap. A second treatment may work for a time, but the same cycle repeats, with resistant populations eventually taking over.
Researchers tracking this process in metastatic breast cancer found that in three out of four patients, a single treatment-resistant cell population eventually dominated the tumor near the end of life. These surviving cells often shared the ability to suppress the body’s immune response and activate growth pathways, effectively shielding themselves from both drugs and the immune system.
This evolutionary pressure is especially fierce in cancers that have spread throughout the body. A metastatic tumor seeded across the liver, lungs, and bones contains billions of genetically diverse cells. Even if a treatment destroys 99.9% of them, the survivors can regrow into tumors that the same treatment no longer touches.
Cancers That Are Incurable but Manageable
“Not curable” doesn’t always mean a short life expectancy. Some cancers are treated more like chronic diseases. Chronic lymphocytic leukemia (CLL) is a good example. It is generally considered incurable, meaning treatment can control it but not permanently eliminate it. Yet for patients with low-risk CLL, the five-year survival rate is about 90%, and the 10-year survival rate is around 86%. Many people with early-stage CLL live for decades, sometimes never needing treatment at all, under a strategy called “watch and wait.”
Higher-risk CLL is a different story, with five-year survival dropping to roughly 23% for the most advanced scores. But the broader point matters: incurable and terminal are not the same thing. Some incurable cancers progress slowly enough that patients die of something else entirely.
Certain low-grade lymphomas, some forms of metastatic breast cancer, and well-controlled metastatic prostate cancer can also follow this chronic pattern, where treatment keeps the disease stable for years without ever fully eliminating it.
What Happens When Cure Isn’t the Goal
When a cancer is deemed incurable, treatment shifts focus. Palliative care aims to control symptoms, reduce pain, and maintain quality of life. It can be provided alongside active cancer treatment at any stage. Hospice care is a more specific step: it’s for patients whose doctors certify a life expectancy of six months or less, and it replaces curative treatment with comfort-focused care.
Entering hospice means Medicare and most insurers stop covering treatments intended to cure the illness and instead cover pain management, emotional and spiritual support, and care for the patient’s family. This isn’t giving up. For many people with incurable cancers, hospice provides better symptom control and, in some studies, even modestly longer survival than aggressive treatment in the final months of life.